(ALGS) Aligos Therapeutics - Ratings and Ratios
Viral, Liver, Therapies, Small, Molecule, Modulators, siRNA
ALGS EPS (Earnings per Share)
ALGS Revenue
Description: ALGS Aligos Therapeutics
Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company that is pioneering the development of novel therapeutics to tackle unmet medical needs in viral and liver diseases, with a robust pipeline of drug candidates in various stages of clinical trials.
The companys lead drug candidate, ALG-055009, is a small molecule THR-ß agonist that has entered Phase 2a clinical trials for the treatment of non-alcoholic steatohepatitis (NASH), a condition with a growing demand for effective treatments. Additionally, Aligos is advancing ALG-000184, a capsid assembly modulator that has completed Phase 1b clinical trials for the treatment of chronic hepatitis B (CHB), and ALG-125755, a siRNA drug candidate in Phase I clinical trials for CHB treatment.
Aligos is also making strides in developing treatments for coronavirus with ALG-097558, which is currently in Phase 2 clinical trials. The companys partnerships with renowned institutions, such as Merck, Emory University, Luxna Biotech Co., Ltd., and Katholieke Universiteit Leuven, underscore its commitment to leveraging cutting-edge research and technology to drive innovation.
Analyzing the
Based on the available data, a forecast for ALGS can be constructed. Given the current price and SMA trends, a potential short-term target could be $7.00, representing a 15% increase from the current price. However, the long-term downtrend and high volatility suggest that investors should exercise caution. If the companys pipeline continues to progress and partnerships yield positive results, a potential long-term target could be $20.00, representing a 230% increase from the current price. Nevertheless, the negative fundamental data and high volatility make this a high-risk investment.
Additional Sources for ALGS Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle
ALGS Stock Overview
Market Cap in USD | 44m |
Sector | Healthcare |
Industry | Biotechnology |
GiC Sub-Industry | Biotechnology |
IPO / Inception | 2020-10-16 |
ALGS Stock Ratings
Growth Rating | -80.0 |
Fundamental | - |
Dividend Rating | 0.0 |
Rel. Strength | -12 |
Analysts | 4.67 of 5 |
Fair Price Momentum | 4.94 USD |
Fair Price DCF | - |
ALGS Dividends
Currently no dividends paidALGS Growth Ratios
Growth Correlation 3m | 86.4% |
Growth Correlation 12m | -41.1% |
Growth Correlation 5y | -90.3% |
CAGR 5y | -55.36% |
CAGR/Max DD 5y | -0.56 |
Sharpe Ratio 12m | -0.14 |
Alpha | -30.09 |
Beta | 0.661 |
Volatility | 122.47% |
Current Volume | 133.8k |
Average Volume 20d | 99.8k |
Stop Loss | 7.6 (-7.8%) |
As of July 09, 2025, the stock is trading at USD 8.24 with a total of 133,840 shares traded.
Over the past week, the price has changed by +11.50%, over one month by +14.60%, over three months by +74.95% and over the past year by -20.00%.
No, based on ValueRay´s Analyses, Aligos Therapeutics (NASDAQ:ALGS) is currently (July 2025) a stock to sell. It has a ValueRay Growth Rating of -80.02 and therefor a clear technical negative rating according to historical growth.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of ALGS is around 4.94 USD . This means that ALGS is currently overvalued and has a potential downside of -40.05%.
Aligos Therapeutics has received a consensus analysts rating of 4.67. Therefore, it is recommended to buy ALGS.
- Strong Buy: 2
- Buy: 1
- Hold: 0
- Sell: 0
- Strong Sell: 0
According to our own proprietary Forecast Model, ALGS Aligos Therapeutics will be worth about 5.6 in July 2026. The stock is currently trading at 8.24. This means that the stock has a potential downside of -31.67%.
Issuer | Target | Up/Down from current |
---|---|---|
Wallstreet Target Price | 90.3 | 996.2% |
Analysts Target Price | 90.3 | 996.2% |
ValueRay Target Price | 5.6 | -31.7% |